EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (NASDAQ: SRDX), the global leader in medical device coating technologies, announced the commercial launch of its most advanced hydrophilic medical device coating technology, Preside™ hydrophilic coatings.

明尼苏达州EDEN PRAIRIE--医疗器械涂层技术全球领导者Surmodics，Inc.（纳斯达克股票代码：SRDX）宣布商业推出其最先进的亲水性医疗器械涂层技术主席™ 亲水涂层。

Preside hydrophilic coatings complement Surmodics’ existing Serene hydrophilic coatings by providing customers with a unique low-friction and low-particulate generation coating to further enhance distal access for neurovascular applications, as well as improve crossing for challenging coronary lesions or chronic total occlusions..

Preside亲水涂层通过为客户提供独特的低摩擦和低颗粒生成涂层来补充Surmodics现有的平静亲水涂层，以进一步增强神经血管应用的远端通路，并改善具有挑战性的冠状动脉病变或慢性完全闭塞的交叉。。

Preside hydrophilic coatings are specifically formulated to meet the challenge of achieving the right balance of enhanced lubricity (reduction in friction) and excellent coating durability (resulting in low particulates) for the next-generation of Neurovascular, Coronary and Peripheral vascular devices.

Preside亲水涂层专门用于应对为下一代神经血管，冠状动脉和外周血管装置实现增强润滑性（减少摩擦）和优异涂层耐久性（导致低颗粒）的适当平衡的挑战。

Surmodics’ Preside hydrophilic coatings allow customers to leverage their existing coating processes resulting in easy implementation in a manufacturing environment..

Surmodics的主导亲水涂层使客户能够利用其现有的涂层工艺，从而在制造环境中轻松实施。。

“Hydrophilic coatings are an essential feature to help medical devices access and navigate tortuous vascular pathways, allowing physicians to reach distal treatment sites for improved therapeutic outcomes,” said Charlie Olson, Senior Vice President, and President of Surmodics’ Medical Device Coatings business.

高级副总裁兼Surmodics医疗器械涂料业务总裁Charlie Olson说：“亲水涂层是帮助医疗器械进入和导航曲折血管通路的基本特征，可让医生到达远端治疗部位以改善治疗效果。”。

“We are pleased to secure the first 510(k) device clearance that leverages this new technology. Our Preside hydrophilic coatings strengthen our existing portfolio and sets a new performance standard for the industry, and the medical device manufacturers we serve.”.

“我们很高兴能够利用这项新技术获得首批510（k）设备间隙。我们的总统亲水涂层加强了我们现有的产品组合，并为行业和我们服务的医疗设备制造商设定了新的性能标准。”。

About Preside™ Hydrophilic Coatings

关于总统™ 亲水涂层

Surmodics’ Preside™ hydrophilic coatings combine a unique industry-leading lubricity and durability, including dramatically improved particulate reduction to address today’s increasing regulatory requirements.

Surmodics主席™ 亲水性涂层结合了独特的行业领先的润滑性和耐久性，包括显着改善颗粒减少，以解决当今日益增长的法规要求。

Preside hydrophilic coatings successfully bond to a wide variety of substrates present on today’s market-leading neurovascular, coronary and peripheral catheters. Preside hydrophilic coatings are applied using Surmodics’ patented Photolink™ UV curing process, which covalently bonds surface treatments to substrates at ambient temperature.

Preside亲水涂层成功地结合到当今市场领先的神经血管，冠状动脉和外周导管上的各种基质上。Preside亲水涂层采用Surmodics的专利Photolink™ UV固化工艺，可在环境温度下将表面处理与基材共价结合。

This flexible technology can easily be incorporated into existing manufacturing processes and can markedly reduce production time and reagent costs compared to both thermal-curing and alternative UV-based chemistries and processes..

与热固化和其他基于紫外线的化学和工艺相比，这种灵活的技术可以轻松地整合到现有的制造工艺中，并可以显着缩短生产时间和试剂成本。。

Surmodics’ chemistries have a proven regulatory record with leading coronary, peripheral, neurovascular and structural heart device applications. Surmodics collaborates with licensed customers to satisfy coating product performance specifications, while navigating through regulatory requirements to accelerate our customer’s speed to market..

Surmodics的化学品具有良好的监管记录，具有领先的冠状动脉，外周，神经血管和结构性心脏装置应用。Surmodics与持牌客户合作以满足涂层产品性能规格，同时通过法规要求进行导航，以加快客户的上市速度。。

About Surmodics, Inc.

关于Surmodics，Inc。

Surmodics is a leading provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. Surmodics also develops and commercializes highly differentiated vascular intervention medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements.

Surmodics是血管内医疗器械和化学和生物组件的性能涂层技术的领先供应商，用于体外诊断免疫测定测试和微阵列。Surmodics还开发和商业化高度分化的血管介入医疗设备，旨在解决未满足的临床需求，并根据最苛刻的要求进行设计。

This key growth strategy leverages the combination of the company’s expertise in proprietary surface modification and drug-delivery coating technologies, along with its device design, development, and manufacturing capabilities. The company’s mission is to improve the detection and treatment of disease.

这一关键的增长战略利用了公司在专有表面改性和药物输送涂层技术方面的专业知识，以及其设备设计，开发和制造能力。该公司的使命是改善疾病的检测和治疗。

Surmodics is headquartered in Eden Prairie, Minnesota. For more information, visit www.surmodics.com. The content of Surmodics’ website is not part of this press release or part of any filings that the company makes with the Securities and Exchange Commission..

Surmodics总部设在明尼苏达州Eden Prairie。欲了解更多信息，请访问www.surmodics.com。surmodics网站的内容不属于本新闻稿的一部分，也不属于本公司与证券交易委员会签订的任何文件的一部分。。